You are here

Preventing asthma exacerbations by reducing viral respiratory infections

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL115903-02
Agency Tracking Number: R44HL115903
Amount: $985,628.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3900 Essex Lane #250
Houston, TX 77027-5181
United States
DUNS: 786704143
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BRENTON SCOTT
 (713) 579-9226
 bscott@pulmotect.com
Business Contact
 BRENTON SCOTT
Phone: (713) 579-9226
Email: bscott@pulmotect.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): An estimated 300 million people worldwide are affected by asthma, causing up to 250,000 deaths per year1,2. Asthma is a personal and public, health and economic burden even in developed countries, where nearly 10% of the population loses substantial time away from work and school. The principal cause of asthma exacerbations, responsible for more than 70%3, is viral respiratory infections. Pulmotect is developing a novel technology to prevent respiratory infections. The lead drug (PUL-042) is a combination of two TLR ligands that stimulates the lungs own innate defense mechanisms, creating a hostile environment for pathogens that can prevent or attenuate respiratory infections. This technology has been validated by both invitro and in vivo experiments and the drug is already progressing in the regulatory process as a treatment to benefit cancer patients during periods of immunocompromise. In the current proposal, we present plans to accomplish milestones that will adv

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government